1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Painful Diabetic Neuropathy Drugs Market
2.2. Global Painful Diabetic Neuropathy Drugs Market, By Drug, 2023 (US$ Million)
2.3. Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2023 (US$ Million)
2.4. Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2023 (US$ Million)
2.5. Global Painful Diabetic Neuropathy Drugs Market, By Geography, 2023 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2023

3. Painful Diabetic Neuropathy Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Painful Diabetic Neuropathy Drugs Market Vendors
3.2. Strategies Adopted by Painful Diabetic Neuropathy Drugs Market Vendors
3.3. Key Industry Strategies
4. Painful Diabetic Neuropathy Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Painful Diabetic Neuropathy Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Anticonvulsants
5.3.2. Tricyclic antidepressants
5.3.3. Serotonin-norepinephrine reuptake inhibitors
5.3.4. Opioid
5.3.5. Topical medications
5.3.6. Selective serotonin reuptake inhibitors

6. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Peripheral
6.3.2. Focal
6.3.3. Proximal
6.3.4. Autonomic

7. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2023 Versus 2032
7.3. Market Segmentation
7.3.1. Online Pharmaceuticals
7.3.2. Retail Pharmacy stores
7.3.3. Hospitals


8. North America Painful Diabetic Neuropathy Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
8.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
8.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
8.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2022-2032, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
8.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
8.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
8.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
8.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
8.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
8.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)

9. UK and European Union Painful Diabetic Neuropathy Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
9.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2022-2032, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.5.1.4.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.5.1.4.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
9.5.1.5. France
9.5.1.5.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.5.1.5.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.5.1.5.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
9.5.1.6.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
9.5.1.6.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)

10. Asia Pacific Painful Diabetic Neuropathy Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
10.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2022-2032, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
10.5.1.3. India
10.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.5.1.4.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.5.1.4.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.5.1.5.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.5.1.5.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
10.5.1.6.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
10.5.1.6.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)

11. Latin America Painful Diabetic Neuropathy Drugs Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
11.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
11.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
11.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2022-2032, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
11.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
11.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
11.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
11.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
11.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
11.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)

12. Middle East and Africa Painful Diabetic Neuropathy Drugs Market, 2022-2032, USD (Million)
12.1. Market Overview
12.2. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
12.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
12.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
12.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2022-2032, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
12.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
12.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
12.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
12.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug, 2022-2032, USD (Million)
12.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2022-2032, USD (Million)
12.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2022-2032, USD (Million)

13. Company Profile
13.1. Daiichi Sankyo Company, Limited
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Johnson & Johnson Services, Inc
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Pfizer Inc.
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Grunenthal GmbH
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. ViroMed Co.
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Collegium Pharmaceutical, Inc
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Acorda Therapeutics, Inc
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. Zydus Pharmaceuticals
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Mallinckrodt, Inc
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. Macleods Pharmaceuticals Ltd.
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. Lupin Pharmaceuticals
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives